Severe, early-onset fetal growth restriction due to placental insufficiency is associated with a high risk of perinatal mortality and morbidity with long-lasting sequelae. Placental insufficiency is the result of abnormal formation and function of the placenta with inadequate remodelling of the maternal spiral arteries. There is currently no effective therapy available. Some evidence suggests sildenafil citrate may improve uteroplacental blood flow, fetal growth, and meaningful infant outcomes. The objective of the Sildenafil TheRapy In Dismal prognosis Early onset fetal growth Restriction (STRIDER) collaboration is to evaluate the effectiveness of sildenafil versus placebo in achieving healthy perinatal survival through the conduct of randomised clinical trials and systematic review including individual patient data meta-analysis.
Five national/bi-national multicentre randomised placebo-controlled trials have been launched. Women with a singleton pregnancy between 18 and 30 weeks with severe fetal growth restriction of likely placental origin, and where the likelihood of perinatal death/severe morbidity is estimated to be significant are included. Participants will receive either sildenafil 25 mg or matching placebo tablets orally three times daily from recruitment to 32 weeks gestation.
The STRIDER trials were conceived and designed through international collaboration. Although the individual trials have different primary outcomes for reasons of sample size and feasibility, all trials will collect a standard set of outcomes including survival without severe neonatal morbidity at time of hospital discharge. This is a summary of all the STRIDER trial protocols and provides an example of a prospectively planned international clinical research collaboration. All five individual trials will contribute to a pre-planned systematic review of the topic including individual patient data meta-analysis.
Petersen SG, Wong SF, Urs P, Gray PH, Gardener GJ. Early onset, severe fetal growth restriction with absent or reversed end-diastolic flow velocity waveform in the umbilical artery: perinatal and long-term outcomes. Aust N Z J Obstet Gynaecol. 2009;49(1):45–51. https://doi.org/10.1111/j.1479-828X.2008.00938.x. CrossRefPubMed
Batton DG, DeWitte DB, Espinosa R, Swails TL. The impact of fetal compromise on outcome at the border of viability. Am J Obstet Gynecol. 1998;178(5):909–15. https://doi.org/10.1016/S0002-9378(98)70522-8. CrossRefPubMed
Product monograph Viagra. Sildenafil as sildenafil citrate. Pfizer Canada Inc., 2015.
Sun X, Wang K, Wang W, Li B. Clinical study on sildenafil treatment of pregnant women with pulmonary arterial hypertension. Zhonghua Fu Chan Ke Za Zhi. 2014;49(6):414–8. PubMed
Molelekwa V, Akhter P, McKenna P, Bowen M, Walsh K. Eisenmenger’s syndrome in a 27 week pregnancy—management with bosentan and sildenafil. Ir Med J. 2005;98(3):87–8. PubMed
Streit M, Speich R, Fischler M, Ulrich S. Successful pregnancy in pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report. J Med Case. 2009;3:7255. CrossRef
Ganzevoort W, Alfirevic Z, von Dadelszen P, Kenny L, Papageorghiou A, van Wassenaer-Leemhuis A, Gluud C, Mol BW, Baker PN. STRIDER: Sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction--a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014;3:23. CrossRefPubMedPubMedCentral
Protocol STRIDER New Zealand/Australia: [doi: 10.5281/zenodo.56150].
Protocol STRIDER Canada: [doi: 10.5281/zenodo.56152].
Protocol STRIDER United Kingdom: [doi: 10.5281/zenodo.56153].
Protocol STRIDER The Netherlands: [doi: 10.5281/zenodo.56148].
Protocol STRIDER Ireland: [doi: 10.5281/zenodo.496143].
DMC Charter STRIDER New Zealand/Australia: [doi: 10.5281/zenodo.56149].
DMC Charter STRIDER Canada: [doi: 10.5281/zenodo.56151].
DMC Charter STRIDER United Kingdom: [doi: 10.5281/zenodo.56154].
DMC Charter STRIDER The Netherlands: [doi: 10.5281/zenodo.56147].
DMC Charter STRIDER Ireland: [doi: 10.5281/zenodo.535768].
Skoog M, Saarimäki JM, Gluud C, Sheinin M, Erlendsson K, Aamdal S, et al. Transparency and registration in clinical research in the Nordic countries. Nordic Trial Alliance, NordForsk; 2015 1–108.
Garattini S, Jakobsen JC, Wetterslev J, Berthele V, Banzi R, Rath A, et al. Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them. European J Intern Med. 2016;32:13–21. CrossRef
Järvinen et al. On blinded analysis and conclusions . J Clin Epidemiol 67 (2014) 769e772.
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Coch Database Syst Rev. 2012;12:MR000033.
Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367:1355–60. CrossRefPubMedPubMedCentral
Molenberghs G, Kenward MG. Missing data in clinical studies. Chichester: Wiley; 2007. CrossRef
- STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials
L. C. Kenny
P. N. Baker
Peter von Dadelszen
C. T. Kariya
B. W. Mol
A. T. Papageorghiou
A. G. van Wassenaer-Leemhuis
K. M. Groom
the international STRIDER Consortium
- BioMed Central
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II